• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Highs On Friday

    9/23/22 2:44:06 PM ET
    $ATXI
    $BHVN
    $IGAC
    $NOAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATXI alert in real time by email

     

    On Friday, 5 companies hit new 52-week highs.

    Intriguing Points From Today's 52-Week Highs:

    • Biohaven Pharma Hldgs (NYSE:BHVN) was the company with the largest market cap to set a new 52-week high.
    • The company with the smallest market cap to set a new 52-week high was Hainan Manaslu Acq (NASDAQ:HMAC).
    • Avenue Therapeutics (NASDAQ:ATXI)'s stock made the biggest move upwards, moving 831.82% to reach a new 52-week high.
    • Natural Order Acq (NASDAQ:NOAC)'s stock actually fell, reaching a new 52-week high but thereafter trading down 0.05%.

    Here is a list of stocks that set new 52-week highs on Friday:

    • Biohaven Pharma Hldgs (NYSE:BHVN) shares reached a new 52-week high of $152.10 on Friday morning, moving up 0.5%.
    • IG Acquisition (NASDAQ:IGAC) shares achieved a new 52-week high on Friday morning, hitting $10.02 with a daily change of up 0.1%.
    • Natural Order Acq (NASDAQ:NOAC) shares were up 0.05% on Friday to hit a new 52-week high of $9.98 for a change of up 0.05%.
    • Avenue Therapeutics (NASDAQ:ATXI) shares achieved a new 52-week high on Friday morning, hitting $6.34 with a daily change of up 831.82%.
    • Hainan Manaslu Acq (NASDAQ:HMAC) stock on Friday broke to a yearly high of $9.99. Shares traded up 0.1%.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $ATXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATXI
    $BHVN
    $IGAC
    $NOAC

    CompanyDatePrice TargetRatingAnalyst
    Biohaven Ltd.
    $BHVN
    4/13/2026$21.00Buy
    Canaccord Genuity
    Biohaven Ltd.
    $BHVN
    2/6/2026$23.00Buy
    Goldman
    Biohaven Ltd.
    $BHVN
    1/21/2026$22.00Sector Perform → Outperform
    RBC Capital Mkts
    Biohaven Ltd.
    $BHVN
    12/3/2025$11.00Buy → Neutral
    H.C. Wainwright
    Biohaven Ltd.
    $BHVN
    11/26/2025$11.00Buy → Neutral
    UBS
    Biohaven Ltd.
    $BHVN
    11/6/2025$9.00Outperform → Mkt Perform
    Bernstein
    Biohaven Ltd.
    $BHVN
    11/5/2025$10.00Buy → Neutral
    BofA Securities
    Biohaven Ltd.
    $BHVN
    9/17/2025$28.00Buy
    Citigroup
    More analyst ratings

    $ATXI
    $BHVN
    $IGAC
    $NOAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

    Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026.Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.In previous clinical studies, taldefgrobep produced meaningful reductions in fat mass while increasing lean muscle mass in healthy adults and other non-obese populations; it has also demonstrated a highly favorable safety and tolerability profile in more than 700 trial participants.In nonclinical studi

    3/19/26 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

    Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradation for immunological diseases, Kv7 ion channel modulation for epilepsy; and myostatin-activin pathway targeting obesity:Inflammation and Immunology:Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of previously elevated thyroid hormones within weeks after dosing a patient with Graves' disease. BHV-1300 has shown the potential for best-in-class reductions of Ig

    3/2/26 4:05:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

    ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 (clenbuterol), a well-characterized small-molecule β2-adrenergic agonist, in clinical development for the treatment of Pompe disease. Pompe d

    2/23/26 8:00:00 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BHVN
    $IGAC
    $NOAC
    SEC Filings

    View All

    SEC Form 10-K filed by Invest Green Acquisition Corporation

    10-K - Invest Green Acquisition Corp (0002075068) (Filer)

    3/30/26 7:44:30 PM ET
    $IGAC
    Blank Checks
    Finance

    SEC Form 10-K filed by Avenue Therapeutics Inc.

    10-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

    3/30/26 5:38:25 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Biohaven Ltd.

    DEFA14A - Biohaven Ltd. (0001935979) (Filer)

    3/13/26 4:57:48 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BHVN
    $IGAC
    $NOAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mehta Kishan

    4 - Biohaven Ltd. (0001935979) (Issuer)

    3/19/26 6:17:49 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Buten Matthew

    4 - Biohaven Ltd. (0001935979) (Issuer)

    3/3/26 6:09:03 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BHVN
    $IGAC
    $NOAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ig Spac Sponsor Llc bought 480,000 units of Class A ordinary shares (SEC Form 4)

    4 - Invest Green Acquisition Corp (0002075068) (Issuer)

    11/26/25 4:39:20 PM ET
    $IGAC
    Blank Checks
    Finance

    VP, Chief Accounting Officer Clark George C. bought $144,770 worth of shares (17,000 units at $8.52) (SEC Form 4)

    4 - Biohaven Ltd. (0001935979) (Issuer)

    11/18/25 7:29:10 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BHVN
    $IGAC
    $NOAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Biohaven with a new price target

    Canaccord Genuity initiated coverage of Biohaven with a rating of Buy and set a new price target of $21.00

    4/13/26 8:51:07 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Biohaven with a new price target

    Goldman initiated coverage of Biohaven with a rating of Buy and set a new price target of $23.00

    2/6/26 8:10:57 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Biohaven from Sector Perform to Outperform and set a new price target of $22.00

    1/21/26 8:29:40 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BHVN
    $IGAC
    $NOAC
    Financials

    Live finance-specific insights

    View All

    Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

    Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

    9/23/24 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

    Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e

    9/20/24 7:09:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

    MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader ("KOL") event highlighting expert perspectives on spinal bulbar muscular atrophy ("SBMA"), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome co

    3/25/24 8:30:00 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BHVN
    $IGAC
    $NOAC
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

    HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

    7/1/24 7:00:00 AM ET
    $BHVN
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

    Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

    5/12/23 4:30:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BHVN
    $IGAC
    $NOAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avenue Therapeutics Inc.

    SC 13G - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/14/24 3:22:45 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/14/24 3:06:46 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care